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miR-17-92 ﬁne-tunes MYC expression and function
to ensure optimal B cell lymphoma growth
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The synergism between c-MYC and miR-17-19b, a truncated version of the miR-17-92 cluster,
is well-documented during tumor initiation. However, little is known about miR-17-19b
function in established cancers. Here we investigate the role of miR-17-19b in c-MYC-driven
lymphomas by integrating SILAC-based quantitative proteomics, transcriptomics and 30
untranslated region (UTR) analysis upon miR-17-19b overexpression. We identify over one
hundred miR-17-19b targets, of which 40% are co-regulated by c-MYC. Downregulation of a
new miR-17/20 target, checkpoint kinase 2 (Chek2), increases the recruitment of HuR to c-
MYC transcripts, resulting in the inhibition of c-MYC translation and thus interfering with
in vivo tumor growth. Hence, in established lymphomas, miR-17-19b ﬁne-tunes c-MYC activity
through a tight control of its function and expression, ultimately ensuring cancer cell
homeostasis. Our data highlight the plasticity of miRNA function, reﬂecting changes in the
mRNA landscape and 30 UTR shortening at different stages of tumorigenesis.
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C
ellular homeostasis consists in the ability to maintain the
internal equilibrium in spite of a changing environment.
The intrinsic capability of the cell to maintain homeostasis
relies on biological robustness1. If this equilibrium is broken, the
cell undergoes either uncontrolled proliferation or programmed
death.
c-MYC (hereafter referred to as MYC) binds to 10–15%
of genomic loci in mammals2. MYC governs many critical
cellular functions, including energy and anabolic metabolism,
proliferation and survival3. It promotes on the one hand cell
growth and cell cycle progression and, on the other, it sensitizes
cells to undergo apoptosis. Thus, under normal circumstances,
MYC-induced cell proliferation is counterbalanced by MYC-
induced cell death. Deregulation of MYC expression and/or
activity is tightly linked to tumour development, as B70% of
human cancers show aberrant MYC function. MYC expression is
regulated at multiple levels, including transcription, translation
and protein stability. At the level of translation, MYC is regulated,
respectively, by an internal ribosome entry site (IRES) located
within the 50 UTR, RNA-binding proteins including HuR and
AUF1, which bind to AU-rich elements located in the 30 UTR,
and various microRNAs (miRNAs)4–6. Interestingly, in addition
to miRNAs that regulate MYC expression, MYC itself regulates
the expression of a broad repertoire of miRNAs, many of which
are key modulators of cell death and proliferation7.
As post-transcriptional silencers of gene expression, miRNAs
play a crucial role in increasing robustness of phenotypic
outcomes8. One way by which miRNAs confer robustness to
the cell is through miRNA-mediated feed-forward loops (FFLs),
whereby a transcription factor (TF) and a miRNA regulate the
same set of protein-coding genes, with the miRNA being
regulated by the same TF9,10. An example of this regulatory
circuit is offered by the interplay between the miR-17-92 cluster,
the TF E2F1 and MYC9. MYC and E2F1 are central regulators of
cell cycle progression and apoptosis and thereby play an essential
role in cellular homeostasis. Since MYC and E2F1 activate each
other at the transcriptional level, there is the risk for the cell to
enter a runaway positive feedback loop, resulting in excessively
high levels of these transcriptional regulators. However, both
factors induce the transcription of miR-17-92, which, in turn,
negatively regulates E2F1 translation11, thus acting as a break on
this positive feedback loop.
miR-17-92 is a polycistron encoding six miRNAs that can be
grouped into four families, based on their seed regions: miR-17,
miR-18, miR-19 and miR-92. miR-17 and miR-19 families are
composed of pairs of miRNAs with identical seed regions:
miR-17/miR-20a and miR-19a/miR-19b-112. As oncomirs, these
miRNAs promote proliferation, inhibit apoptosis and induce
tumour angiogenesis13,14. Yet, in some contexts, the miR-17
family negatively regulates cell proliferation15–17 and inhibits cell
migration and invasion18,19. Therefore, it has become widely
accepted that miR-17-92 has the potential to act either as an
oncogene or as a tumour suppressor, depending on the cellular
context.
Interestingly, in the last few years an increasing body of
evidences has shown that 30 UTRs undergo signiﬁcant shortening
during tumorigenesis20. Since 30 UTR shortening alters the pool
of mRNA targets of a given miRNA, this may determine distinct
outcomes of the same miRNA’s activity at different stages of
tumour development.
The interplay between miR-17-92 and MYC has already been
extensively studied during MYC-dependent B cell lymphomagen-
esis. The enforced expression of the truncated version of the
cluster, miR-17-19b, was shown to synergize with MYC in
accelerating tumorigenesis in the Em-MYC mouse lymphoma
model21. miR-19 was identiﬁed as the main effector of this
synergism, by counteracting MYC-induced apoptosis through
PTEN silencing22,23. Yet, in spite of the wealth of information
collected on the activity of miR-17-19b during lymphoma onset,
the role of the cluster in established MYC-dependent tumours
remains largely unknown.
In this study, we address the function of miR-17-19b in
established MYC lymphomas, at a stage when MYC has
pervasively reprogrammed the transcriptome of the tumour cell.
By applying an integrated approach centred on SILAC (Stable
Isotope Labelling by Amino acids in Cell culture24)-based
quantitative proteomics, transcriptomics and 30 UTR analysis,
we identify more than a hundred miR-17-19b targets.
A large portion of identiﬁed targets (about 40%) is predicted to
be under the control of MYC, highlighting miRNA-mediated
FFLs as an important mode of gene regulation. We also reveal
that miR-17-19b indirectly downregulates MYC translation
through the newly identiﬁed miR-17-19b target, checkpoint
kinase 2 (Chek2). Downregulation of Chek2 by miR17/20 leads to
increased recruitment of HuR/RISC to MYC mRNA, which
inhibits its translation. In line with these results, we observe that a
subtle increase in miR-17-19b levels reduces the ﬁtness of
lymphoma cells, both in vitro and in vivo.
In conclusion, our data demonstrate that miR-17-19b sustains
homeostasis of MYC-driven lymphomas by ﬁne-tuning MYC
expression, thus protecting tumour cells from harmful effects
linked to excessive MYC levels.
Results
Mild perturbation of miR-17-19b affects lymphoma cell proteome.
We proﬁled the expression levels of both MYC and the mature
forms of miR-17-19b members in human Burkitt lymphoma (BL)
cell lines and in MYC-transformed pre-tumoral and mature
B cell lymphomas isolated from k-MYC transgenic mice25.
We observed a substantial increase in MYC protein levels at the
transition between pre-tumoral and tumoral B cells, which
correlated with increased levels of miR-17-19b members in most
mouse and human BL cells (Fig. 1a). This result is consistent with
previous observations showing MYC-dependent transcriptional
activation of the miRNA cluster11.
To investigate the role of miR-17-19b in full-blown B cell
lymphomas, we perturbed the system by increasing the
expression of the cluster in l-MYC lymphoma B cells, whose
endogenous miR-17-19b levels are comparable to those of human
BL (Fig. 1a, right panel). We infected lymphoma cells with a
retroviral vector encoding miR-17-19b or, as a control, a
retrovirus lacking the cluster (Supplementary Fig. 1a). Both
vectors expressed green ﬂuorescence protein (GFP) as a reporter,
which was used to enrich for infected cells by cell sorting. Global
miRNA expression analysis of sorted miRNA-infected cells
(miR cells) revealed two- to ﬁvefold higher expression levels of
miR-17-19b members, whereas other miRNAs were not affected
(Supplementary Fig. 1b). Quantitative reverse transcription–PCR
analysis (RT–qPCR) indicated a preferential overexpression of
miR-17 and miR-20 (Supplementary Fig. 1c, left panel), showing
a relative miRNAs stoichiometry similar to that of the
endogenous cluster (Fig. 1a, right panel). The increased level of
transgenic miRNAs was also reﬂected by their engagement within
the RISC complex, as monitored by real-time PCR analysis
of miRNAs co-immunoprecipitated by Ago2 (Supplementary
Fig. 1c, right panel).
To identify miR-17-19b targets we made use of a systems
biology approach that integrates in silico miRNA-target predic-
tion with quantitative proteomics and transcriptomics analysis on
acute induction of the cluster. We employed SILAC-based
quantitative proteomics to determine the impact of miRNAs on
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global protein output. In parallel, a transcriptome analysis was
performed using microarray proﬁling. This approach provided a
comprehensive picture of ﬂuctuations in both mRNA and protein
levels that resulted from modulation of miR-17-19b expression
(Fig. 1b; Supplementary Fig. 2). We identiﬁed and quantiﬁed over
4,500 proteins with high precision and statistical conﬁdence, and
proﬁled transcript levels of almost 21,000 genes (Supplementary
Table 1). High reproducibility of the two replicates (#2567-1 and
#2567-2) was conﬁrmed by an overlap of 85% for identiﬁed
proteins (Supplementary Fig. 2c) and the high correlation
(r¼ 0.83) between heavy/light (H/L) protein ratios measured in
the two data sets (Fig. 1c).
Gene ontology (GO) analysis of the transcriptome and
proteome data showed that although the proteome represents a
subset of the transcriptome, it is not biased towards or against
any speciﬁc functional category (Supplementary Fig. 2d).
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Figure 1 | Mild overexpression of miR-17-19b in B cell lymphoma triggers a global proteomic response. (a) Expression levels of MYC (left panel) and the
mature forms of miR-17-19b components (right panel) were proﬁled in Epstein–Barr virus (EBV) positive (Daudi and Raji) and EBV negative (CA46 and
Ramos) human Burkitt lymphoma cell lines, as well as in primary lymphomas and pre-tumoral (PT) B cells isolated from l-MYC transgenic mice. Wild-type
mouse splenic B cells were used as controls. (b) Scheme of the SILAC experiment. Control and miR-17-19b overexpressing cells (miR cells) were cultured in
light (L) and heavy (H) media, respectively. Labelled cells were combined in 1:1 ratio and analysed by liquid chromatography–tandem mass spectrometry. In
parallel, from the same samples, total RNA was prepared and analysed by microarray. Data were subjected to statistical and functional analysis. Intensity
peak ratios between heavy and light peptides (H/L ratio) reﬂect changes in protein expression. (c) Reproducibility of the SILAC proteome in the two
experimental data sets, #2567-1 and #2567-2 (d) Log2-transformed H/L protein ratio distributions of the two functional experiments (miR cells versus
control for #2567-1 in red and #2567-2 in blue) and of the control experiment (control cells versus control cells, in black) indicate a strong proteome
response upon induction of the cluster, with both, up- and downregulated proteins. (e) The comparison of log2 fold changes at protein and mRNA levels
shows low correlation (r¼0.51), with signiﬁcantly larger protein dispersion. (See related Supplementary Figs 1 and 2).
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miRNA-overexpressing tumour cells responded signiﬁcantly to
the modulation of miR-17-19b, showing both up and down-
regulation of a number of proteins (Fig. 1d). The larger dispersion
in protein fold changes compared with transcripts revealed
the prevalent response of the proteome to the modulation of
miR-17-19b (Fig. 1e). Western blot and real-time PCR analyses
conﬁrmed the results obtained by SILAC and microarrays,
respectively (Supplementary Fig. 2e,f).
To identify miR-17-19b direct targets, we intersected the
experimental data with a list of genes predicted as targets of the
miRNA cluster using two different algorithms. With TargetScan,
we identiﬁed seed-matching sequences that are also evolutionary
conserved. A second algorithm, developed in-house, com-
plemented the ﬁrst approach and searched in an unbiased
manner for 7mer and 8mer seed-matching sequences genome
wide. We compared the downregulation of predicted targets to
non-targets at both the protein and transcript levels. While we
could observe mild but statistically signiﬁcant responses at
the protein level, no signiﬁcant response was detected at the
corresponding mRNA levels (Fig. 2a). We conﬁrmed the
downregulation of several known miR-17-92 targets, such as
E2f1 (ref. 11), Cyclin D1 (ref. 17), Stat3 (ref. 26) and Atm27 upon
miR-17-19b overexpression (Fig. 2b and Supplementary Fig. 3a).
Surprisingly, instead, tumour suppressor Pten, identiﬁed as a
miR-17-19b target in the Em-Myc lymphoma model22,23, was not
downregulated in established l-MYC lymphomas (Fig. 2b).
In light of the extensive 30 UTR shortening observed in cancer
cells20, we considered the possibility that this phenomenon
could affect signiﬁcantly the repertoire of miR-17-19b targets in
established lymphomas. Hence, we performed RNA-Seq analysis
of l-MYC transgenic B-lymphoma cells, focusing in particular on
30 UTR regions. A comparison of our data with publicly available
RNA-Seq data sets obtained from mature B cells of healthy mice
indicated a general depletion of transcripts with longer 30
UTR isoforms and a corresponding enrichment (Po2.2e 16,
calculated by two-sided Wilcoxon signed rank test) for shorter
mRNA isoforms in tumour cells (Fig. 2c, left panel). Interestingly,
in tumour B cells, the RNA-Seq analysis identiﬁed several Pten
mRNA isoforms with variable 30 UTR lengths, including a large
proportion of transcripts with sensibly shorter 30 UTRs, without
any miR-17-19b-binding site (Supplementary Fig. 3b). This
observation supports the concept that 30 UTR shortening may
contribute to the ‘escape’ of Pten from miR-19-dependent
silencing.
Inspired by this ﬁnding, we manually curated all miR-17-19b
putative target mRNAs, analysing their 30 UTRs to verify the
actual presence of miR-17-19b-binding sites (Fig. 2c, right panel).
With this set of ﬁltered targets, we re-analysed the global miRNA
response at the proteome level, to assess the contribution of the
cluster and also of individual miRNAs. Indeed, the cumulative
distribution analysis showed improved response for the whole
cluster and statistically signiﬁcant downregulation of miR-17 and
miR-19 predicted targets compared with non-targets (Fig. 2d).
We also observed weak evidence for downregulation of miR-18
targets, whereas no signiﬁcant response was detected for miR-92,
which was our negative control since it was not overexpressed in
our experimental system (Supplementary Fig. 3c).
Among the predicted targets, 369 were signiﬁcantly down-
regulated at the proteome level before 30 UTR ﬁltering
(Supplementary Table 2, High and Low Conﬁdence Targets; see
Supplementary Fig. 4 for cut-off deﬁnition), and 271 were left
after manual curation of 30 UTRs for actual miR-17-19b-binding
sites (Supplementary Fig. 3d). Of these, 148 proteins were selected
as the highest conﬁdence class, based on reproducibility among
multiple biological replicates (Supplementary Table 2, High
Conﬁdence Targets). From this group, only ﬁve were signiﬁcantly
downregulated at both the protein and mRNA level, while the rest
were regulated at the protein level only (Fig. 2e). In addition,
15 targets downregulated at the transcript level were not detected
in the SILAC proteome (Supplementary Table 2, Transcriptome
Targets).
miR-17-19b impinges on MYC function. Ingenuity pathway
analysis (IPA) of the molecular and cellular functions associated
with newly identiﬁed miR-17-19b targets in l-MYC lymphomas
revealed that several pathways relevant for cancer onset and
maintenance are affected, including Cell Death and Cell Cycle
Regulation (Fig. 3a, left panel). In addition to known miR-17-92
targets playing key roles in these two processes, such as E2f1
(ref. 11), Cyclin D1 (ref. 17), Stat3 (ref. 26) and Atm27, we
identiﬁed 36 novel miR-17-19b targets involved in their
regulation (Supplementary Table 2, Cell Cycle_Apoptosis).
Interestingly, several categories, that IPA indicated as
modulated by the cluster, are also MYC-regulated processes.
Thus, to further explore the cooperation between MYC and
miR-17-19b, we intersected the experimental miR-17-19b target
data set with a list of MYC targets, inferred from ChIP-Seq data
from BL cells28. We observed that 40% of the experimentally
identiﬁed miR-17-19b targets are also bound by MYC in human
BL cells (Fig. 3a, right panel). Interestingly, MYC/miRNA-co-
regulated targets included several genes encoding TFs, suggesting
a model whereby miR-17-19b acts centrally within a multi-
layered gene expression network. To further explore this
hypothesis, we focused on selected TFs (E2F family members,
STAT3 and ZBTB7A), for which predicted targets were available
Figure 2 | 30 UTR shortening alters the pool of miR-17-19b targets in full-blown lymphoma. (a) Cumulative distributions of normalized protein H/L ratios
(left panel) and mRNA fold changes (right panel) upon miR-17-19b overexpression, shown for non-targets (black), miR-17-19b targets predicted by
TargetScan (blue), an in-house algorithm for unbiased searching of sites corresponding to 8mer (red) and 7mer-m8 seeds (green). (b) Western blot
validation of a set of known miR-17-19b targets (left panel; see related Supplementary Fig. 3a). Dotted line separates targets that are conﬁrmed (upper part)
from Pten, which is not downregulated in our model (lower part). H2A.X and Vcl were used as loading controls. SILAC-based MS analysis indicates that
Pten is not downregulated upon miR-17-19b overexpression (right panel). (c) Analysis of proximal poly(A) site usage in two samples from primary l-MYC
B-lymphoma cells (#2567; in blue) reveals a trend towards the usage of shorter 30 UTRs in a full-blown lymphoma relative to B cells (in black; ENCODE
project). The frequency of proximal poly(A) site usage is plotted on the x-axis, while number of transcripts is plotted on the y-axis (left panel). Examples
of distal (Ccnd1 mRNA) and proximal (Gnl1 mRNA) poly(A) signal usage, which generate longer and shorter 30 UTRs, respectively (right panel). Red
arrows indicate the poly(A) sites that are used. UTR, untranslated region; ORF, open reading frame; p(A), poly(A). See related Supplementary Fig. 3b.
(d) Cumulative distributions of normalized protein H/L ratios for the cluster and for miR-17 and miR-19 families, upon manual ﬁltering for the presence of
miR-17-19b seeds within 30 UTRs. Non-targets are shown in black, miR-17-19b targets predicted by TargetScan are in blue and those predicted by the
in-house algorithm for unbiased searching of sites corresponding to 8mer in red and 7mer-m8 seeds in green. (See related Supplementary Fig. 3c). (e) Log2
fold changes of 148 signiﬁcantly downregulated miR-17-19b targets at the protein level (blue, for the deﬁnition of the statistical cut-off see Supplementary
Fig. 4) and mRNA levels (red, #2567-1). The dotted lines represent the cut-off values of±1.5-fold change that set signiﬁcant outliers in the transcriptome.
(See related Supplementary Table 2).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9725
4 NATURE COMMUNICATIONS | 6:8725 | DOI: 10.1038/ncomms9725 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
miR-17 miR-19
0.0 0.5–0.5 1.0–1.0 0.0 0.5–0.5 1.0–1.0
TargetScan 8mer 7mer-m8 Non-Targets
P = 9.97x10–3
P = 2.43x10–3
P = 2.00x10–5
P = 2.93x10–2
P = 1.02x10–2
P = 1.23x10–2
0.0
Lo
g 2
 
fo
ld
 c
ha
ng
e
Cu
m
ul
at
ive
 fr
ac
tio
n
Cu
m
ul
at
ive
 fr
ac
tio
n
0.5
1.0
–0.5
–1.0
–1.5
-2.0
–2.5
–3.0
–3.5
Transcriptome, log2 fold change
Proteome, log2 normalized (H/L) ratio
P = 3.79x10–3
P = 8.80x10–4
P = 1.11x10–3
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0
0.2
0.4
0.6
0.8
1.0
0.0 0.5–0.5 1.0–1.0
Log2 normalized (H/L) ratio
0.0 0.5–0.5 1.0–1.0
Log2 mRNA fold change
Cu
m
ul
at
ive
 fr
ac
tio
n
P = 6.46x10–1
P = 7.54x10–1
P = 3.79x10–1
TargetScan 8mer 7mer-m8 Non-targets
Cu
m
ul
at
ive
 fr
ac
tio
n
Frequency of proximal poly(A) site usage
B-lymphoma cells 1
B-lymphoma cells 2
0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9
Longer 3′ UTR Shorter 3′ UTR
0
200
400
600
800
1,000
1,200
N
um
be
r o
f t
ra
ns
cr
ip
ts B cells
Cyclin D1
E2f1
Stat3
H2A.X
Atm
Pten - YVYYYSYLLK
Light (control)
687.8539
z=2
m/z
20
40
60
80
100
R
el
at
iv
e 
in
te
ns
ity
687
0
688 689 690 691 692 693
Heavy (miR)
691.8612
z=2
Co
ntr
ol
Pten
Vcl
m
iR
 ce
lls
p(A) p(A)p(A)
p(A)
p(A)
p(A)
Gnl1
 NM_008136.2
ORF3′ UTR
miR-19 miR-17/20
p(A)
p(A) p(A) p(A) p(A)
p(A)
p(A)
ORF3′ UTR
Ccnd1
NM_007631.2  
Proximal  p(A)Proximal  p(A)
miR-17/20
Distal p(A) Distal p(A)
P = 8.80x10–4
P = 1.30x10–4
P= 3.70x10–4
0.0 0.5–0.5 1.0–1.0
Log2 normalized (H/L) ratio Log2 normalized (H/L) ratio Log2 normalized (H/L) ratio
Cu
m
ul
at
ive
 fr
ac
tio
n
miR-17-19b
Example of longer 3′ UTR Example of shorter 3′ UTR
Proteome Transcriptome
55
25
130
180
15
55
130
1.0
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9725 ARTICLE
NATURE COMMUNICATIONS | 6:8725 | DOI: 10.1038/ncomms9725 | www.nature.com/naturecommunications 5
& 2015 Macmillan Publishers Limited. All rights reserved.
Tfb2mAcox3
Kpna4
miR-17
Kpna3 Ino80
C330019G07Rik
MYC
Acbd5
Grsf1
miR-19
G3bp2
Elp3
Sept7
Fam162a
2610301G19Rik
Rexo2 Ubap2
Jmy
Atm
Lyplal1
Mtap7d1
Deptor
Racgap1
Gpd1l
Rpia
Rab22a
Snx8
Pdp2
Xpot
Phip
M6pr
Itga4
Map3k5
Fam3c
Ttf2
Akap1
Ccm2Sypl
miR-18
Polr3d
D14Abb1e
Tsr1
N6amt1
Zbtb7a
Dpysl2
Stat3
Ugp2
Zmpste24
Wrnip1
1300001I01Rik
Nup153
Adss
Tmed3
Dennd4a
Mrpl17
Ivns1abp
Lclat1
Nbeal2
MYC
Vcl
Co
ntr
ol 
ce
lls
m
iR
 ce
lls
Control
cells
M
YC
 
m
R
N
A 
le
ve
ls
O
D:
 A
25
4
Vcl
Vcl
MYC
MYC
Control
cells
miR cells
CHX (min):
5′ UTR
3′ UTR
MYC
0.00
0.25
0.50
0.75
1.00
1.25
1.50
1.75
–
lo
g 
(B
–H
 P
 v
a
lu
e)
Ce
ll d
ea
th
 a
nd
 s
ur
viv
al
Ce
llu
la
r m
ov
em
en
t
M
ol
ec
ul
ar
 tr
an
sp
or
t
Pr
ot
ei
n 
tra
ffi
ck
in
g
Ce
ll c
yc
le
N
uc
le
ic
 a
ci
d 
m
et
ab
ol
ism
 
Ce
llu
la
r a
ss
em
bl
y 
an
d 
O
rg
an
iza
tio
n
ce
ll 
m
or
ph
ol
og
y
Ce
llu
la
r c
om
pr
om
ise
Ce
llu
la
r f
un
ct
io
n 
an
d 
M
ai
nt
en
an
ce
Po
st
-tr
an
sl
at
io
na
l m
od
ific
at
io
n
Li
pi
d 
m
et
ab
ol
ism
Sm
al
l m
ol
ec
ul
e 
bi
oc
he
m
ist
ry
Ce
llu
la
r g
ro
wt
h 
an
d 
pr
ol
ife
ra
tio
n
Ce
llu
la
r d
ev
el
op
m
en
t
Pr
ot
ei
n 
sy
nt
he
sis
0
0.5
1
1.5
2
miR
cells
HMWP
Control cells
miR cells
0
10
20
30
40
50
1 2 3 4 5 6 7 8 9 10 11
%
 o
f M
YC
 m
RN
A Control cells
miR cells
0
10
20
30
40
50
1 2 3 4 5 6 7 8 9 10 11
%
 o
f M
fg
e8
 m
RN
A Control cells
miR cells
   40S   60S  80S
40S
80S
60S
LMWP
HMWPLMWP
HMWP40S LMWP
miR cells
N
or
m
al
iz
ed
 M
YC
in
te
ns
ity
*
0.00
0.40
0.80
1.20
5′-
MY
C
5′-
MY
C-3
′
MY
C-3
′
–
MYC
Actin
5′ UTR
3′ UTR
5′-
MY
C
5′-
MY
C-3
′
– MY
C-3
′
MYC/actin:
55
130
130
130
70
55
70
55
55
40
1.33 1.30 0.90 0.70
0 15 30 60 90
11101 2 3 4 5 6 7 8 9
80S60S
40S 80S60S
Threshold
Figure 3 | miR-17-19b counterbalances MYC expression and function. (a) Ingenuity pathway analysis (IPA) for the newly identiﬁed miR-17-19b targets
(high and low conﬁdence targets, Supplementary Table 2), left panel. Graphical representation of the MYC-centred regulatory network of the targets
co-regulated by MYC and miR-17-19b (right panel). (b) Western blot analysis of MYC expression in control and miR cells (upper panel). Real-time PCR
analysis of MYC mRNA in control and miR cells (middle panel). Histogram represents the averages from three independent experiments with error bars
representing s.e.m. MYC expression is normalized to B2m mRNA. Western blot analysis of MYC stability in cycloheximide-treated control and miR cells
(lower panel; Vcl is used as negative control). (c) Polysomal analysis indicates less efﬁcient translation of MYC mRNA in miR cells relative to control. Equal
amount of the control and miR cells lysates were fractionated through sucrose gradient to generate polysome proﬁles by measuring absorbance at 254 nm.
The relative distribution of MYC and Mfge8 mRNAs (as control) on polysome gradients was assessed by RT–qPCR analysis of the RNA present in all
11 fractions, and displayed as percentage of total mRNA (% of mRNA). Arrow indicates the direction of sedimentation; 40S and 60S, small and large
ribosomal subunits, respectively; 80S, monosomes; LMWP (fractions 6–8) and HMWP (fractions 9–11), low- and high-molecular weight polysomes,
respectively. The polysome proﬁle from control cells is in pink while that from the miR-17-19b-overexpressing cells is in blue. (d) Western blot analysis of
MYC protein levels upon enforced expression of constructs bearing a MYC-coding region with either a 50 UTR, 50 and 30 UTR or 30 UTR regions in miR cells
(left panel) and the quantiﬁcation (n¼ 3; t-test, equal variances, one-tail, *Pr0.05; middle panel) show impaired expression of the construct bearing the 30
UTR. A schematic representation of the constructs is displayed in the right panel. (See related Supplementary Fig. 5).
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in B cells29. The intersection of our experimental target data set
with a list of targets for each of the selected TFs conﬁrmed the
existence of sub-networks, involving not only these TFs but also
their own targets (Supplementary Fig. 5a). Altogether, these data
point towards the involvement of miR-17-19b in various gene
expression feedback and FFLs, suggesting a role of these miRNAs
in buffering a MYC-centred regulatory network against internal
and external perturbations.
miR-17/20 decreases MYC translation via the Chek2/HuR axis.
We were prompted to monitor the expression level of MYC
itself by the observation that miR-17-19b acts on several
MYC-regulated processes. Remarkably, we found that MYC was
downregulated upon a mild increase of miR-17-19b, despite not
being a direct target of these miRNAs (Fig. 3b, upper panel). To
dissect how miR-17-19b regulates MYC expression, we ﬁrst
investigated its transcriptional regulation (Fig. 3b, middle panel)
and protein stability by treating cells with cycloheximide,
a drug which blocks translational elongation and thus permits
monitoring protein stability (Fig. 3b, lower panel). miR-17-19b
caused neither signiﬁcant mRNA downregulation nor reduced
MYC protein stability. We then investigated the effect of
miR-17-19b on MYC translation. Polysomal analysis revealed
increases in sub-monosomes and low molecular weight
polysomes, mirrored by a corresponding reduction in heavy
molecular weight polysomes of MYC transcripts in miR cells
compared with control cells (Fig. 3c and Supplementary Fig. 5b).
This result indicated that translation of MYC mRNA is impaired
upon a mild increase of miR-17-19b. By overexpressing distinct
MYC transgenes that differ in their 50- and/or 30 UTRs in miR
cells, we could identify the 30 UTR as the region containing
binding sites for putative trans-acting factors that negatively
regulate MYC translation, in a miR-17-19b-dependent manner
(Fig. 3d and Supplementary Fig. 5c,d). In the presence of both the
30- and 50 UTRs this effect was not observed, suggesting that the
50 UTR is compensating the effect detected with the 30 UTR alone.
The 50 UTR of MYC contains an IRES which is developmentally
controlled30. It is active during embryogenesis and downregulated
in adult mice. Therefore, it is possible that some factors, required
to repress the IRES-regulated translation in adults, are titrated out
by excessive levels of the 50 UTR of MYC, leading to the IRES
de-repression.
It has been previously described that the RNA-binding protein
HuR binds MYC 30 UTR and regulates MYC expression in a
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context-speciﬁc way: the full-length protein (35 kDa) can both
stimulate31 and inhibit32 translation, while the cleaved form
(25 kDa, cleavage product 1 (CP-1)) inhibits MYC translation33.
To test the hypothesis that miR-17-19b reduces MYC level by
affecting HuR interaction with MYC mRNA, we performed
ribonucleoprotein-immunoprecipitation (RIP) analysis and we
observed that HuR immunoprecipitates higher amounts of MYC
mRNA in miR cells than in control cells (Fig. 4a). An RNA pull-
down assay using as bait four overlapping regions (A–D)
of MYC 30 UTR conﬁrmed the preferential binding of HuR to
fragments B and D (Supplementary Fig. 6a), in agreement with
previous ﬁndings32. Consistent with the binding of let-7b/c to a
region overlapping segments A and B, we observed preferential
binding of Ago2 to fragment B (Fig. 4b). Therefore, our results
suggest that HuR recruits the Ago2-RISC to ﬁnely regulate MYC
translation, in accordance with previous data32. However, we also
detected the CP-1 isoform bound to the same regulatory regions
(Fig. 4b, longer exposure), indicating a more complex scenario in
our model system than previously reported.
Our SILAC experiment and western blot analysis showed no
changes in HuR abundance upon miR-17-19b overexpression
(Supplementary Table 1 and Supplementary Fig. 6a, see input in
the right panel). Thus, the increased recruitment of HuR to MYC
30 UTR could result from either improved binding or increased
translocation of the protein from nucleus to cytoplasm. Since we
did not observe any change in the subcellular distribution of HuR
(Supplementary Fig. 6b), we focused on the regulation of HuR
binding to MYC mRNA. The interaction of HuR to a target
mRNA is tightly regulated by a complex pattern of phosphoryla-
tion at distinct sites, suggesting that a mild increase in miR-17-
19b modulates HuR phosphorylation state. To verify this, we
compared phospho-HuR in control and miR cells. We performed
IP experiments using as baits either anti-HuR or anti-phospho-
Serine/Threonine antibodies, followed by western blot analysis
using anti-phospho-Serine/Threonine and anti-HuR antibodies,
respectively (Fig. 4c left panel, Supplementary Fig. 6c,d). In both
experiments, we detected a mild, yet reproducible, decrease of
CP-1 phosphorylation in miR cells compared with controls
(Fig. 4c, right panel). The phosphorylation on CP-1 was
conﬁrmed by treatment with l protein phosphatase
(Supplementary Fig. 6e). Interestingly, phosphorylation seems
to occur primarily on CP-1, with the phosphorylation signal on
HuR full-length visible only in the anti-Phospho-Serine/Threo-
nine-IP (Supplementary Fig. 6d). This observation hints towards
the existence of a correlation between phosphorylation and
cleavage of HuR, adding an additional level of complexity to HuR
mechanism-of-action.
Although HuR can be phosphorylated by several kinases, such
as PKCa, PKCd and Cdk14, Chek2 has been described as the
most prominent regulator of HuR binding to target mRNAs34.
Remarkably, Chek2 emerged as a novel miR-17/20 target from
the SILAC experiment and its downregulation was also conﬁrmed
by western blot analysis (Supplementary Table 2 and Fig. 5a).
In silico prediction uncovered a miR-17/20 binding site within the
Chek2 30 UTR, the existence of which was validated by RNA-Seq
data (Fig. 5b). The luciferase assay conﬁrmed the downregulation
of the reporter gene when fused to the truncated version of the
Chek2 30 UTR bearing the miR-17/20-binding site (Fig. 5c, left
panel). Mutation of the miR-17/20-binding site completely
rescued the downregulation of the reporter gene (Fig. 5c, left
panel). In accordance with these results, endogenous Chek2
transcript accumulated in sub-monosomes and low molecular
weight polysomes, indicating translational repression, in cells
overexpressing miR-17-19b (Fig. 5c, right panel; and
Supplementary Fig. 7a). These data together conﬁrmed Chek2
as a miR-17/20 target in our model.
To corroborate the hypothesis that Chek2 activity affects MYC
expression, we used PV1019, a highly selective inhibitor of this
kinase35. We ﬁrst validated the effectiveness of the inhibitor
in human BL cell lines on the known Chek2 target, Cdc25c
(Supplementary Fig. 7b). Twenty-four-hour treatment of
l-MYC lymphoma cells with increasing amounts of PV1019
led to progressive reduction of MYC protein level (Fig. 5d,
left panel), without affecting the stability of the protein
(Supplementary Fig. 7c). A time course analysis of MYC
expression showed that already 3 h after the treatment with
10 mM PV1019, MYC protein levels were signiﬁcantly reduced,
with the effect being more evident in miR cells compared with
controls (Fig. 5d, right panel). The same result was observed in
the human BL cell lines Ramos and Daudi (Fig. 5e). To pinpoint
whether Chek2 activity regulated MYC expression through its 30
UTR, we employed the constructs bearing either the 50- or the 30
UTR region. Upon transient expression of MYC transgenes,
PV1019 treatment led to a strong downregulation of the construct
bearing the 30 UTR in miR-17-19b-dependent manner, thus
directly linking miR-17-19b regulation of MYC protein level to
the kinase activity of Chek2 (Fig. 5f). Moreover, PV1019
treatment reduced HuR phosphorylation (Supplementary
Fig. 7d) and boosted its binding to fragments B and D,
with consequent decrease of MYC protein level, even
after short treatments with the drug (for example, 30min;
Supplementary Fig. 7e).
Taken together, our data suggest that miR-17-19b reduces
MYC translational efﬁciency indirectly, through the downregula-
tion of the novel target Chek2. Chek2 reduction causes increased
binding of HuR to MYC mRNA, which in turn ﬁnely regulates
MYC mRNA translation.
MYC/miR-17-19b equilibrium sets B-lymphoma cell ﬁtness. To
assess the biological relevance of miR-17-19b modulation in
lymphoma maintenance, we chose two independent l-MYC
lymphomas showing endogenous levels of miR-17-19b similar
(#2567) or lower (#2646) than those of human BL (Fig. 1a, right
panel). In both l-MYC lymphomas, a modest increase of miR-
17-19b led to impaired proliferation, a reduction in G1-to-S
transition and a signiﬁcant increase in the fraction of apoptotic
cells (Fig. 6a). The reduction in cell cycle progression, together
with impaired tumour survival, resulted in a competitive growth
disadvantage of miR cells, which progressively disappeared when
co-cultured with their control counterparts (Fig. 6b). A similar
effect was also observed when a 1:1 mixture of control and miR
transgenic cells was injected into immunoproﬁcient syngeneic
mice to give rise to secondary tumours in vivo. Real-time PCR
performed on genomic DNA isolated from lymphoid organs of
tumour-bearing animals revealed the preferential loss of miR cells
as revealed by quantiﬁcation of retroviral DNA speciﬁcally car-
rying the miRNA cluster (Fig. 6c). These results indicate that a
mild perturbation of miR-17-19b levels in established MYC
lymphomas is sufﬁcient to interfere with in vivo tumour growth
as a result of miR-17-92 modulation of MYC expression. Indeed,
a modest increase in MYC levels (Fig. 3d and Supplementary
Fig. 5c) was sufﬁcient to fully restore the ﬁtness of lymphoma
cells expressing transgenic miR-17-19b (Fig. 7a).
These results suggest a model whereby MYC activity in tumour
cells (including supra-physiological enhancement of anabolic
processes) is ﬁnely counterbalanced by selected miRNAs to
ultimately sustain immortal growth of the tumour. According to
this model, MYC may sustain miR-17-92 inhibitory activity, for a
subset of co-regulated targets, by selecting mechanisms that
prevent 30 UTRs from shortening. Remarkably, in agreement with
this model, we observed that miR-17-19b targets, co-regulated by
MYC, contain 30 UTRs longer than those from miRNA-targets
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that are not co-regulated by MYC (Fig. 7b and Supplementary
Fig. 8). This provides evidence for an essential role of MYC/miR-
17-92 FFLs throughout tumour development.
Discussion
Gene expression silencing mediated by miRNAs can have
different effects, depending on the cellular context. Global
downregulation of miRNA expression is a common feature of
human tumours36. Yet, the miR-17-92 cluster is highly expressed
in a variety of cancers21, suggesting an important role in tumour
maintenance. Downregulation of the tumour suppressor Pten by
miR-19 was identiﬁed as a relevant contribution of the cluster to
MYC-driven lymphomagenesis in the pre/pro-B Em-MYC
lymphoma model22,23. Remarkably, Pten was not down-
regulated in established l-MYC lymphomas upon acute pertur-
bation of miR-17-19b levels. Absence of Pten downregulation
may depend on Pten 30 UTR shortening, which leads to its escape
from miR-19 regulation.
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The effect of miRNAs on cell function depends on the
particular transcriptional proﬁle of the cell. Alternative poly-
adenylation has only recently gained attention as a key regulator
of the dynamics of gene regulation37. Any change in the lengths
of 30 UTRs may inﬂuence the fate of the mRNA as a result of
altered binding of RNA-binding proteins and miRNAs38,39. For
example, in rapidly proliferating T cells, proliferation-related
genes, which contain binding sites for miR-155 and miR-17-92,
have signiﬁcantly shorter 30 UTRs relative to non-targets40.
Similarly, cancer cells express mRNAs with overall shorter 30
UTRs, where the shortening was linked to the activation of
oncogenes, due to escape from miRNA silencing20.
In this study, we made use of several complementary
approaches to investigate the effects of miR-17-19b on different
levels of gene regulation in malignant B cells. In silico prediction
analyses of miRNA targets suffers from a high rate of false
positives, due to the incomplete sequence complementarity
between miRNAs and their targets and the large heterogeneity
of 30 UTRs, as revealed by next generation sequencing technology.
The combined strategy described here underlines the power
of intersecting quantitative proteomics with in-depth 30 UTR
analysis to gain an accurate and comprehensive picture of
miRNA-mediated gene regulation.
Upon acute increase of miR-17-19b expression in MYC-
transformed B cells, we observed a predominant response
at the proteome level, relative to the transcriptome. These
results are consistent with the view that miRNAs control gene
expression through translational repression and mRNA
degradation41,42.
Surprisingly, our analysis showed that MYC itself is
downregulated upon acute induction of miR-17-19b in lym-
phoma cells. MYC downregulation has been previously linked to
the activity of the miR-17 family in MCF-7 cells17. However, the
molecular details of this mechanism remained elusive, given that
MYC is not a direct target of this miRNA family. Our data
suggest that miR-17/20, through downregulation of the Chek2
kinase and the consequent reduction of HuR phosphorylation,
increases HuR binding to MYC mRNA, leading to inhibition of
MYC translation.
The RNA-binding protein HuR/Elav1 (embryonic lethal
abnormal vision-like protein 1) plays an important function
in mRNA biology (mRNA processing, trafﬁcking, decay and
translation). HuR elicits distinct gene expression outcomes in
different contexts, including tumorigenesis and/or tumour
maintenance43,44. An additional layer of complexity in HuR
biology derives from its ability to modulate translation in a
context-speciﬁc manner34. HuR activity and binding to target
mRNAs is regulated by a complex, cell-speciﬁc, pattern of
post-translational modiﬁcations45. For example, increasing
cellular polyamines in rat intestinal epithelial cells stimulates
Chek2 activity and Chek2-dependent HuR S100 phosphorylation,
which positively regulates HuR binding to MYC mRNA and
MYC translation31. Of note, mutations of the other two residues
targeted by Chek2 cause opposite outcomes. Speciﬁcally, while
mutation of S88 increases association of HuR to MYC mRNA,
mutation of T118 does not impinge on HuR binding. Moreover,
the cleaved form of HuR (CP-1) was also shown to repress MYC
translation on hypoxic stress33. Therefore, understanding of
how context-speciﬁc dynamic changes of HuR post-translational
modiﬁcation patterns modulate HuR activity remains an
unachieved, yet challenging goal.
In addition, given the high number of miR-17-19b targets in
our system, we cannot exclude that other mechanisms also
contribute to the observed downregulation of MYC.
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ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms9725
10 NATURE COMMUNICATIONS | 6:8725 | DOI: 10.1038/ncomms9725 | www.nature.com/naturecommunications
& 2015 Macmillan Publishers Limited. All rights reserved.
The importance of the ﬁne equilibrium between MYC and
miR-17-92 during B cell tumorigenesis has been emphasized by
Olive et al.46, who reported that miR-92, by inhibiting
degradation of MYC, stimulates uncontrolled cell growth while
increasing at the same time programmed cell death. The authors
propose a scenario whereby two distinct miRNAs of the miR-17-
92 exert antagonizing functions on the regulation by MYC on
apoptosis during lymphomagenesis. Speciﬁcally, while miR-92
stimulates p53-dependent apoptosis and ensures elimination of
pre-malignant MYC-overexpressing cells, miR-19 represses
MYC-induced programmed cell death46.
Our study extends this model by adding players and further
emphasizes the role of miR-17-92 in guaranteeing the correct
balance between opposite biological outcomes in cancer
cells (Fig. 7c). The ﬁne-tuning of MYC exerted by miR-17-92
in cancer cells guarantees at any given time point a tight control
over its transforming activity, with the ultimate goal to
sustain tumour maintenance (Fig. 7c). The acute perturbation
of miR-17-19b levels in aggressive lymphomas allowed us to
appreciate the ﬁne equilibrium between miR-17-92 and MYC in
tumour cells and the biological consequences of this tight balance
on in vivo tumour growth.
In conclusion, our study illustrates the plasticity of miR-17-19b
function, which is tightly connected to dynamic changes in
the mRNA landscape that accompany tumour formation and
maintenance. At the molecular level, we unravelled the inhibitory
effect of miR-17-19b on MYC expression and function in
established MYC-driven lymphomas. From a cancer-biology
perspective, we envisage a scenario whereby miR-17-19b
maintains cellular homeostasis by protecting cancer cells from
exceedingly high and potentially harmful MYC levels, ultimately
guaranteeing its ability to sustain continuous tumour growth.
Methods
Tumour cell lines and cell culture. Mouse B-lymphoma cell lines (#2567, #2646,
#2676, #2564 and #2487) were established after in vitro culture of primary
lymphomas isolated from l-MYC transgenic mice25. Tumours were cultured
in vitro in B cell medium (DMEM (Invitrogen) supplemented with 10% foetal calf
serum (FCS), 100Uml 1 of penicillin and streptomycin (Lonza), 2mM Glutamine
(Lonza), 1mM non-essential amino acids (Gibco), 1mM Na-pyruvate (Gibco)
and 50mM b-mercaptoethanol (Gibco)). After 2–3 weeks of in vitro culture,
an expanding population of IgMþB220þ lymphoma cells was established. Clonal
status of the tumour was conﬁrmed by Southern blotting analysis of Igk V gene
rearrangements. Procedures involving animals were approved by IFOM animal
Ethics Committee and the Italian Ministry of Health. Human BL cell lines
(CA46, RAMOS, Raji and Daudi) were cultured in RPMI medium (Invitrogen),
supplemented with 10% FCS, 100Uml 1 of penicillin and streptomycin, 2mM
Glutamine, 1mM Na-pyruvate and 1mM Hepes. All cells were cultured at 37 C in
a humid atmosphere with 5% CO2. CA46 and RAMOS cell lines are not present in
the ICLAC list of misidentiﬁed cell lines, while Daudi and Raji are classiﬁed as
misidentiﬁed. However, both cell lines, Daudi and Raji, are identiﬁed as human BL
cells, which was the only criteria for the choice of the cell lines used in the study.
Cloning and retroviral gene transduction. Plasmid pMIG-miR-17-19b was
generated by PCR ampliﬁcation of miR-17-19b, a truncated version of miR-17-92,
from mouse genomic DNA (BamHI_miR-17, FW_50-CGGGATCCGTCAGAA
TAATGTCAAAGTGCT-30 XhoI_miR-19b, RV_50-CCGCTCGAGCACTACCA
CAGTCAGTTTTGCAT-30). The ampliﬁed fragment was cloned into the GFP
containing retrovirus-mediated gene expression vector pMIG II by BamHI–XhoI
digestion and DNA sequenced for veriﬁcation. The virus was produced by Phoenix
cells and transfected by Ca2Cl protocol in B-lymphoma cell lines. A spin infection
was performed in triplicate with a total number of 2 105 cells per well.
At 48 h post infection, the efﬁciency of transduction was evaluated by ﬂow
cytometric analysis monitoring GFP expression, and subsequently GFP-sorted.
All experiments were performed within ﬁrst 10, post infection, cell passages.
RNA extraction and real-time PCR analysis. Total RNA was prepared using
mirVANA miRNA Isolation kit (Ambion), according to the manufacturer’s
speciﬁcation for total RNA isolation. The complementary DNA was produced
using the Reverse Transcriptase ImPromII (Promega), starting from 1 mg of total
RNA. One-tenth of the reaction was used for real-time PCR reactions with FAST
SYBR Green Master Mix (Applied Biosystems) and in 7,900HT Fast Real-Time
PCR System. All experiments were performed in triplicate, unless speciﬁed.
Relative changes in mRNA levels of target genes were calculated by normalizing the
amount of transcripts to the levels of H2a.x or B2m.
For RNA-Seq, total RNA was puriﬁed using Trizol (Invitrogen), treated with
Turbo DNase (Ambion), puriﬁed with phenol-chloroform and precipitated with
EtOH. Libraries for RNA-Seq were then prepared with TruSeq RNA Sample Kits
v2 (Illumina), following manufacturer’s instruction for enrichment of poly(A)
mRNAs. RNA-Seq was performed on Illumina HiSeq 2,000 sequencer.
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Figure 7 | The regulatory loop involving miR-17-92 and MYC maintains
lymphoma homeostasis. (a) A modest increase of MYC protein level
restores growth rate of miR-17-19b-overexpressing cells. Growth rate of the
cells is displayed as line plots, which are the mean±s.e.m. from three
independent experiments. (b) Frequency of poly(A) site usage analysis for
‘regulated’ and ‘non-regulated’ miR-17 targets. The comparison between
regulated and non-regulated targets reveals longer 30 UTRs for the class
of regulated targets, but only when they are co-regulated by MYC.
A Mann–Whitney U test was used to determine statistical differences
between the two distributions (*Pr0.05). (See related Supplementary
Fig. 8). (c) Proposed model for miR-17-92 role in maintaining lymphoma
homeostasis is schematized (modiﬁed from the study by Aguda et al.9).
A ‘cancer zone’ is deﬁned by a dynamic equilibrium between proliferation
and apoptosis. During B cell lymphomagenesis, miR-17-92 antagonizes
MYC-induced apoptosis by downregulation of Pten, operating as an
oncogene. In full-blown lymphoma, instead, miR-17-92 inhibits cell cycle
progression and increases apoptosis through a tight regulation of MYC
expression and function, acting as a tumour suppressor.
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miScript Reverse Transcription Kit, miScript Primer Assay and miScript SYBR
Green PCR Kit (Qiagen) were used according to the manufacturer’s instructions
for miRNAs proﬁling.
SILAC experiment. Control and miRNA-expressing cells were grown in SILAC
media24 (lysine- and arginine-free DMEM/Ham’s F12 (1:1), supplemented with
10% dialyzed foetal bovine serum (Invitrogen)). ‘Heavy’ and ‘Light’ media were
prepared by adding 0.146 g l 1 13C6, 15N2 L-Lysine and 0.84 g l 1 13C6 15N4
L-Arginine (Sigma) or the corresponding non-labelled amino acids, respectively.
After eight replications, equal numbers (12 106) of heavy and light cell
populations were mixed and lysed in 300 ml RIPA buffer. Denaturation of protein
extracts (150 mg) was achieved by incubation in 6M urea/2M thiourea for 30min,
followed by reduction with 1mM DTT (30min). Thyols were carboxymethylated
with 5mM IAA for 20min and the proteins were digested by addition of 1 mg LysC
for 3 h. After fourfold dilution with 50mM ammonium bi-carbonate, 1 mg trypsin
was added and the sample was incubated overnight at 37 C. The digestion was
terminated by acidifying the sample to pHo2 with 100% TFA. Product peptides
were separated according to their isoelectric point by isoelectrofocusing
electrophoresis using the Agilent 3,100 OFFGEL Fractionation Kit (Agilent
Technologies)47. Samples were prepared and separated according to the
manufacturer’s protocol. After separation, peptides mixtures were reconstituted
with 1% TFA and desalted on C18 STAGE tips48.
Liquid chromatography and Mass spectrometry. Peptides eluted from C18
Stage-tips were analysed by nano-liquid chromatography (LC) using an Agilent
1,100 Series nano-ﬂow LC system (Agilent Technologies), directly interfaced to a
LTQ-FT Ultra mass spectrometer (ThermoFisher Scientiﬁc, Bremen, Germany).
The nanolitre ﬂow LC was operated in one column set-up with a 15 cm analytical
column (75 mm inner diameter, 350mm outer diameter) packed with C18 resin
(ReproSil, Pur C18AQ 3 micro-meter, Dr Maisch, Germany). Solvent A was 0.1%
FA and 5% ACN in ddH2O and solvent B was 95% ACN with 0.1% FA. Samples
were injected in an aqueous 0.1% TFA solution at a ﬂow rate of 500 nlmin 1. We
used 140min gradient from 2 to 60% acetonitrile in 0.5% acetic acid. Nanoelec-
trospray ion source (Proxeon, Odense, Denmark) was used with a spray voltage of
1.5–2.0 kV. No sheath, sweep and auxiliary gasses were used and capillary tem-
perature was set to 180 C. The mass spectrometer was operated in a data-
dependent mode to automatically switch between mass spectrometry (MS) and
tandem MS (MS/MS) acquisition. In the LTQ-FT Ultra, full scan MS spectra were
acquired at a target value of 2,000,000 ions and with a resolution of 100,000 (full
width at half maximum) at 400 m/z. In the LTQ MS/MS, spectra were acquired
using a target value of 5,000 ions and the 5 most intense ions were isolated for
CID-fragmentation.
Analysis of MS data. Identiﬁcation and quantiﬁcation of proteins was carried out
using the MaxQuant software package v. 1.2.2.5 (refs 49,50). The integrated
Andromeda algorithm was used to search the IPI Mouse protein sequence database
(v.3.87, Sep 2011). A maximum of two missed cleavages were permitted. Oxidation
of methionine and acetylation of the protein N terminus were used as variable
modiﬁcations. Carbamidomethylation of cysteine was used as a ﬁxed modiﬁcation.
A minimum peptide length of six residues was required and the maximum
false discovery rates were set to 1% at both the protein and peptide levels.
MaxQuant-deﬁned protein groups, which matched reversed protein sequences
or contaminants, were excluded. To determine at high conﬁdence a qualitative
proteome, each protein group required a minimum of two peptide matches, of
which at least one was unique from all peptides identiﬁed in #2567-1 and #2567-2
combined.
These two data sets were analysed separately for quantiﬁcation. Therefore, to
determine an accurate quantitative proteome, a minimum of three ratio counts
(RC42) was required from peptides identiﬁed either in #2567-1 or in #2567-2.
Details of the composition of the acquired and ﬁltered proteome are presented in
Supplementary Table 1.
Deﬁning cut-off for deﬁnition of responders in the SILAC experiment. To
deﬁne a cut-off for responders, we made use of a triplicate SILAC proteome of
WT:WT cells to examine technical variation in the experimental proteome and
deﬁne a cut-off point. By examining the protein ratio distribution over the full
intensity range and the protein ratios separated into bins of intensities of size 300
(Supplementary Fig. 4a, panels 2–11), and estimating the quantiles at 0.5 and 99.5%
(denoted by red horizontal lines also given numerically in Supplementary Fig. 4b)
provides limits which describe the range in which 99% of the data lie. The cut-off
point used to deﬁne responders was taken as the median of the cut-off points for
each of the binned proteomes, resulting in the ﬁgures in the ﬁnal row of the table in
Supplementary Fig. 4b. This gives at least a 5% false positive rate for classes C–J,
10% in class B and a maximum of 20% in class A.
GO analysis. The reference genome-based proteome was constructed using all
mouse protein identiﬁers present in the IPI database (v.3.87, September 2011).
MGI identiﬁers corresponding to all genes were mapped to biological process
GO terms, using the gene association ﬁle made available by the Mouse Genome
Informatics database51. These GO terms were then matched to GO slim terms,
made available by the same database.
Microarray hybridization and RT–qPCR validation. Affymetrix expression array
was performed by Affymetrix-GeneChip Mouse gene 1.0 ST Array hybridization
with total RNA from SILAC experiment in three biological replicates.
Complementary DNA was synthesized using random hexamers, oligo d(T) and the
SuperScript II Reverse transcriptase System (Invitrogen). Real-time PCR validation
of microarray data was done by Cogentech (IFOM-IEO Campus), with TaqMan
Gene Expression Assays from Applied Biosystems for following genes: Itga4 (Assay
ID: mm00439770_m1), Atm (mm01177457_m1), Runx1 (mm00486762_m1),
Bcl2l11 (mm01333921_m1), Bax (mm00432050_m1), Ctgf (mm00515790_g1),
Pten (mm00477210_m1), E2f3 (mm01138831_m1), Uhrf2 (mm00520043_m1),
Cd38 (mm00483146_m1), Ptk2b (mm00552827_m1), Pbk (mm00517793_m1),
Pfkp (mm03053257_s1), Slc1a5 (mm00436603_m1), Acin1 (mm00479895_m1),
Rasa3 (mm00436272_m1), Gmfb (mm00517681_m1), Aifm1 (mm00442540_m1),
Htra2 (mm00444846_g1), Kras (mm00517494_m1), N-ras (mm03053787_s1),
Cdc42bpb (mm00805507_m1), Capn (mm00482964_m1), Stat3 (mm03053490_s1),
Dffb (mm00432822_m1), Plcg (mm01242530_m1), B2m (mm00437762_m1).
Primers used for mRNA proﬁling of known miR-17-19b targets, upon miR-17-
19b overexpression (H2ax was used for normalization):
E2f1_FW: 50-ATGGGCCACCTGAGGGTCCC-30 ;
E2f1_RV: 50-CCTCGTGGGGTGGGGAGAGG-30
CyclinD1_FW: 50-GCTGCAGTGCTGTAGGCCCC-30 ;
CyclinD1_RV: 50-GGCCCTCAAGGGTCCTGCCT-30
Stat3_FW: 50-GGGCGACCCTATCGTGCAGC-30 ;
Stat3_RV: 50-GACTAAGGGCCGGTCCGGGT-30
Atm_FW: 50-TCTGCTGTCTGCGCACGTCC-30 ;
Atm_RV: 50-GCAGGAGTTGCTGAGCGGCT-30
H2ax_FW: 50-CGTGGTCTCTCAGCGTTGTTCGC-30;
H2ax_RV: 50-TGAAGGCCGGCGCGTGAAGA-30 .
Analysis of microarray data. Expression proﬁling of total RNAs was performed
on raw.CEL ﬁles using the R statistical programming language (R Development
Core Team, Vienna) and tools from the Bioconductor project52 and the
aroma.affymetrix package53,54. The robust multi-chip average method was used for
background adjustment, normalization and summarization55 and quality control
information was also made available. Annotation data were extracted using the
mogene10sttranscriptcluster.db R/Bioconductor package.
Cell extracts and western blot analysis. Total cell extracts were prepared in
standard RIPA buffer (10mM Tris-HCl, pH 8.0, 1% Triton, 0.1% SDS, 0.1%
Deoxycholate, 140mM NaCl, 1mM EDTA, 1mM DTT, 1mM PMSF and protease
inhibitor cocktail (Roche, Basel, Switzerland)). Nuclear and cytoplasmic fractions
were prepared as described previously56. Brieﬂy, the cytoplasmic fraction was
obtained by lysing cells in a low salt buffer (100mM Hepes, pH 6.8, 5mM KCl,
5mM MgCl2, 0.5% NP-40, 5mg l 1 Aprotonin, 5mg l 1 Leupeptin, 0.5mM
PMSF, 0.5mM Na-butyrate, 5mM Na-vanadate and 5mM NaF), while for the
nuclear extract in a high salt buffer containing 250mM NaCl. DNA was digested
with Benzonase for 10min at 37 C. Western blots were performed following
standard protocols: protein extracts were resolved by SDS–PAGE, transferred to
PVDF membrane (Immobilon-P, Millipore) using Bio-rad electrophoresis systems
and probed with primary and secondary antibodies in 5% milk solved in TBS with
0.1% Tween. Proteins were visualized by using the ECL system (Amersham or
Bio-Rad). Primary antibodies against MYC (sc-N-262), Ppp2r2a (PP2A B55-alpha
2G9; sc-81606), E2F1 (KH95; sc-251), GMF-b (C-17; sc-46999), Cdkn1b (sc-528)
and N-RAS (C-20 sc-519) were purchased from Santa Cruz; Stat 3 (9132), Atm
(2873), Pten (138G6), Aifm1 (AIF, 4642), Bax (2772), PBK/T0PK (4942), Ptk2b
(PYK2; 3292), Ccnd1 (DC56) and Ube2a (5293) from Cell Signaling; H2AX
(ab11175), Htra2 (ab75982) and PFKP (ab72680) from AbCam; Vcl (V9131) from
Sigma and CHK2 from Millipore. Vcl antibody was used at dilution 1:20,000, while
all other antibodies were used at 1:1,000 dilution.
Chemiluminescent signal was detected by a ﬁlm or by ChemiDoc XRSþ
(Bio-Rad), which was also used for the quantiﬁcation of the chemiluminescent
signal. The full blots are shown in Supplementary Figure 9.
Seed analysis to identify miRNA targets. The seed analysis was performed
considering four miRNA-families, miR-17 (comprise miR-17 and miR-20), miR-
18, miR-19 (comprise miR-19a and miR-19b) and miR-92. Two approaches were
used to detect potential miR-17-19b-binding sites for all protein-coding mouse
genes. First, conserved target sites were identiﬁed using TargetScan Mouse v6.2
(ref. 57). Then, 7mer-m8 and 8mer sites were identiﬁed also in an unbiased manner
using a custom Perl script. This script was applied to all isoforms of mouse 30
UTR sequences, obtained from Ensembl v67 (ref. 58) using the Biomart
data-mining tool59.
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RNA-Seq data and poly(A) sites usage analysis. RNA-Seq data sets of about
200–250 million paired end reads each were aligned to the mm9 mouse reference
genome using Tophat2 in conjunction with Bowtie, with default parameters60–62.
More than 85% of the sequences were mapped. Reads failing to map both on
mouse transcriptome or genome were mapped on the locus of the human MYC
gene, to assess the transcriptional activity of the transgene, resulting in B500,000
more reads mapped per sample (0.2%).
The mouse poly(A)-Seq annotations of ‘Merck Research Laboratories’ from the
UCSC Genome Browser database63 reports strand-speciﬁc poly(A) sites found in
ﬁve mouse tissues (brain, kidney, liver, testis and muscle). We combined these data
in a unique strand-speciﬁc putative poly(A) site list, merging adjacent sites when
their distance was o20 bp. We assigned the resulting poly(A) sites to the
corresponding mouse RefSeq mRNAs and non-coding RNAs. For each of the 7,157
RNAs with at least 2 putative poly(A) sites and an average coverage greater than 10
in at least one of our samples, we computed the average read coverage in a 100-bp
window upstream of the ﬁrst (most upstream, proximal) and the last (most
downstream, distal) poly(A) site of the RNA. We employed as control adult
(8 weeks) B cell (CD19þ ) RNA-Seq coverage data, from the ENCODE project,
available at the UCSC Genome Browser database. Differential poly(A) site usage
was estimated as follows: U¼ (Af—Al)/Af, where Af and Al are the average read
coverage in the 100-bp windows before the ﬁrst and last poly(A) site, respectively.
Values of U close to 0 thus indicated preference for poly(A) sites at the 30 of the
transcript, while values close to 1 pointed towards preferential usage of upstream
poly(A) sites.
Statistical analysis for frequency of proximal poly(A) site usage. For all high
conﬁdence miRNA targets, each family of miRNA targets was separated into two
groups of targets: those that were joint MYC targets and those with no evidence for
MYC regulation. The distributions of proximal poly(A) site usage (see ‘RNA-Seq
data and poly(A) sites usage analysis’) were displayed in box plots and compared
through a Mann–Whitney U-test, where Po0.05 implies a signiﬁcant difference
between the two distributions.
Selection of miR-17-19b target genes. The list of computationally identiﬁed
mouse genes containing one or more potential miR-17-19b-binding sites was
intersected with quantiﬁed proteome and transcriptome data. Targets of different
miRNAs were considered to be signiﬁcantly downregulated if their associated
protein expression was measured in either #2567-1 or #2567-2 with 42 ratio
counts and a normalized H/L ratio o0.855. This cut-off was derived through an
assessment of technical variation in the experimental proteome. miRNA targets
were considered to be downregulated at the transcriptome level if the fold change
was log2o 0.5. We inspected manually the expression of 30 UTR regions in our
RNA-Seq data to ensure that the miRNA-binding sites were present in expressed
isoforms. Genome coordinates (mm9) of all predicted miRNA-binding sites were
determined and uploaded to the UCSC genome browser, and were displayed along
with RNA-Seq data from Sample 1. A total of 1,478 miRNA targets, robustly
quantiﬁed in our proteomics data, was inspected manually and annotated as either:
YES, YES*, NO or ND. YES implies strong evidence for the presence of at least one
binding site for any miRNAs from the cluster, while YES* refers to weak evidence.
NO implies strong evidence that the expressed 30 UTR does not contain any
miRNA-binding site for miRNAs from the cluster. No Data implies that the
coordinates determined for the miR-17-19b-binding sites were outside the anno-
tated boundaries of all transcripts related to the gene framework, which could
derive from differences between Ensembl and RefSeq databases.
Cumulative distributions to display regulatory effect of miRNA action.
Normalized H/L protein ratio distributions for miRNA-target and non-target genes
were compared for each seed type: Targetscan, unbiased 8mer and unbiased
7mer-m8. The signiﬁcance of expression downregulation between these groups was
evaluated using a one-sided Kolmogorov–Smirnov test. This downregulation was
visualized using empirical cumulative distribution function (ECDF) curves. To
discriminate the effect of individual miRNAs, this analysis was performed both for
combined and separate members of the miR-17-92 cluster. A P value o0.05
inferred signiﬁcant downregulation of miRNA targets relative to non-targets.
Similar analysis was performed for transcript fold changes. All statistical analyses
were performed in R/Bioconductor software.
Construction of MYC/miRNA FFLs. We intersected the list of MYC gene targets
obtained from the study by Seitz et al.28, (accession: GSE30726) with the
experimentally derived miR-17-19b responders (high and low conﬁdence targets,
Supplementary Table 2). Transcriptional targets of E2F1, E2F3, E2F4, E2F5, LRF
and STAT3 were obtained from protein–DNA interactions annotated in predicted
B cell interactome data29. Lists of targets for each TF were intersected with the list
of miR-17-19b targets. Statistical signiﬁcance of enrichment of jointly regulated
targets was evaluated by Fisher’s exact test (Po0.05, two-sided).
HuR and Ago2 RIP. HuR-IP was performed as previously described64. To prepare
cytosolic extracts, control and miR cells were lysed with passive lysis buffer (20mM
Hepes pH 7.4, 100mM KCl, 0.3% NP-40, 5mM MgCl2, protease inhibitors
(Roche), 1mM Na3VO4, 50mM NaF and 10mM b glycerol-phosphate).
Extracts were pre-cleared with mouse IgGs (sc-2025) for 30min, at 4 C. IgGs were
removed by incubating extracts with protein-G magnetic beads (Dynabeads,
Invitrogen) for 30min, at 4 C for. Pre-clearing was performed in IP buffer 150mM
NaCl, 100mM Tris-HCl pH 7.4, 1mM DTT, 1mM EDTA. Extracts were incubated
for 2 h at 4 C with beads previously coupled with HuR antibody (Abcam,
ab136542) overnight. Beads were washed four times with IP buffer. Bound proteins
were eluted with Laemmli buffer, and analysed by SDS–PAGE coupled with
immunoblotting. Ago2-IP was performed starting from 2 106 cells by using the
RiboCluster Proﬁler RIP-Assay Kit (MBL), according to the manufacturer’s
instructions with anti-mouse Ago2 antibody (018–22021, Wako).
RNA–biotin pull-down analysis. RNA pull-down assay was performed as
previously described64 with following modiﬁcations: primers for the transcripts
spanning the 150-nt fragments from 30 UTR of MYC mRNA (NM_002467)
were from Kim et al.32 The T7 RNA polymerase sequence
T7: 50-CCAAGCTTCTAATACGACTCACTATAGGGAGA-30 .
30 UTR-A (1891–2042):
FW_50-(T7)GGAAAAGTAAGGAAAACGATTCC-30;
RV_50-CCAATTTGAGGCAGTTTACATTATG-30 ;
30 UTR-B (1991–2146):
FW_50-(T7)GCTGAGTCTTGAGACTGAAAGA-30 ;
RV_50-CATTGTGTAAATCTTAAAATTTTT-30;
30 UTR-C (2096–2250):
FW_50-(T7)CAGATTTGTATTTAAGAATTGTT-30 ;
RV_50-TACCTATAATACTAGGTACTAT-30 ;
30 UTR-D (2199–2357):
FW_50-(T7)GCAGTTACACAGAATTTCAATCCT-30 ;
RV_50-TTTTTTTTTTAAGATTTGGCTCAATGA-30 .
Polysome analysis. Polysome analyses from B cells were done as previously
described65. Brieﬂy, 40ml of 7.5 105 cells per ml in exponential phase were
treated with 0.1mgml 1 cycloheximide for 10min at 37 C, washed twice with
ice-cold PBS and lysed in 350 ml of polysome extraction buffer (PEB: 15mM Tris
pH 7.4, 15mM MgCl2, 0.3M NaCl, 15% Triton-100, 0.1mgml 1 cycloheximide,
40Uml 1 RNasin, complete protease inhibitor cocktail). Extracts were incubated
10min on ice and centrifuged at 13,000 r.p.m. for 10min at þ 4 C. Supernatant
(equal amount of material or supernatant from equal starting number of cells) was
layered onto 10ml 10–50% sucrose gradient (prepared in PEB without Triton-100)
and ultracentrifuged at 35,000 r.p.m. for 190min in a SW41 rotor at þ 4 C.
Fractions of 1ml were collected. Prior to the RNA extraction, 1 ng of luciferase
mRNA synthesized in vitro was added as internal control for the extraction
of the RNA. Polysomal fractions were treated with 10 ml 10% SDS, 25 ml 0.5M
EDTA and 4 ml 20mgml 1 proteinase K for 30min at 55 C. RNA was isolated
with Quick-RNA Mini prep (ZYMO RESEARCH), and afterwards analysed
by RT–qPCR. Obtained qPCR values for speciﬁc genes were normalized
to luciferase.
Luciferase reporter assay. Primers corresponding to 62 nt of Chek2 30 UTR
containing miR-17/20-binding site wild-type (30 UTR WT) or mutated (30 UTR
MUT)66 were annealed and cloned downstream of the luciferase reporter gene into
the pmirGLO vector (Promega) using XbaI and SacI restriction enzymes.
HeLa cells were seeded in 48-well dishes at 4 104 cells per ml. The day after
cells were transfected with 0.5 mg of pmirGLO, pmirGLO—30UTR WT and
pmirGLO—30UTR MUT using Lipofectamine LTX (Invitrogen). About 24 h after
transfection, luciferase signal was assessed using Dual-Glo Luciferase Assay System
(Promega) according to the manufacturer’s instructions.
(30 UTR WT: FW-50-CCGTGGAAATCTGGGCTGATTGTTTGATGACCTGC
ACTTTAGATTTCTTTCTTTCTTTCTTTCT-30 ;
RV-50-CTAGAGAAAGAAAGAAAGAAAGAAATCTAAAGTGCAGGTCAT
CAAACAATCAGCCCAGATTTCCACGGAGCT-30 ;
30 UTR MUT: FW-50-CCGTGGAAATCTGGGCTGATTGTTTGATGACCTG
ATACAGAGATTTCTTTCTTTCTTTCTTTCT-30;
RV-50-CTAGAGAAAGAAAGAAAGAAAGAAATCTCTGTATCAGGTCATC
AAACAATCAGCCCAGATTTCCACGGAGCT-30).
Ingenuity pathway analysis. IPA was done with standard settings (mammals—all
tissues and cell lines; experimentally observed and high predicted conﬁdence).
Electroporation. Plasmids overexpressing MYC-coding region with either a 50
UTR, 50 and 30 UTR or 30 UTR67 were electroporated by using Microporator
Digital Bio according to manufacturer’s instruction. Brieﬂy, 2 mg of DNA and
1.3 106 cells were resuspended in 100ml buffer T and pulsed with 990V for a
duration of 40ms. Electroporated cells were seeded in multiwall 12 (two
electroporations per well) in the ﬁnal volume of 1ml of medium. The next day,
cells were brought to the concentration of 0.1 106 cells in the presence of
0.5 mgml 1 of puromycin.
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Preparation of B cell suspension from lymphoid organs. Single-cell suspensions
were obtained by grinding spleens and lymph nodes between frosted slide glasses
followed by ﬁltering through 70 mm nylon meshes (Becton Dickinson, USA).
Femurs were ﬂushed using a syringe containing 10ml of B cell medium to obtain
bone marrow cells. Erythrocyte lysis from spleen was achieved by incubating cell
suspensions in 1ml of a 9:1 (v/v) solution of 0.15M NH4Cl and 0.17M Tris-HCl,
pH 7.65 for 3min on ice. Red blood cell lysis was interrupted adding 10 vol of B cell
medium. Cells were centrifuged at 1,200 r.p.m. at 4 C and resuspended in B cell
medium before counting.
B cells were puriﬁed from a heterogeneous cell suspension by magnetic cell
sorting (MACS; Miltenyi Biotec, Germany). Cell populations were stained with
anti-CD19-antibodies conjugated with magnetic beads (10 ml per 106 cells) for
30min on ice and washed twice with degased MACS buffer (PBS, pH 7.2,
supplemented with 0.5% bovine serum albumin, 2mM EDTA; degas buffer by
applying vacuum). Next, cells were applied to LS columns in a magnetic ﬁeld68 and
the columns were washed three times with 3ml of MACS buffer. Columns were
then removed from the magnetic ﬁeld, 5ml of B cell medium were added and
CD19-positive cells were ﬂushed out using a plunger. Purity achieved by MACS
was over 95%. Puriﬁed cells were washed once with cold PBS and pelleted for RNA
and protein extraction.
Growth curve, cell cycle proﬁling and apoptosis assay. Growth curves were
generated by seeding 2 105 cells per well in 12-well plates, in triplicate. At 2-day
intervals, cells were counted and the average number of cells was calculated. The
experiment was done in three biological replicates.
For assessment of proliferative status of #2567-1 cells, control and miRNA-
expressing cells were pulsed with bromodeoxyuridine (BrdU, Sigma) for 5min.
After extensive washings, cells were ﬁxed and prepared for FACS analysis using
standard procedure. Brieﬂy, 2 106 cells were ﬁxed in 70% ethanol for 30min at
4 C, denatured in 2N HCl for 25min at room temperature, neutralized with 0.1M
sodium borate for 2min and stained with anti-BrdU antibody (Beckton Dickinson)
for 1 h at room temperature in 1% BSA/PBS. Anti-mouse Alexa 647, diluted in 1%
BSA/PBS for 1 h at room temperature was used as the secondary antibody. Cells
were ﬁnally resuspended in 1ml PI (0.025mgml 1) containing 0.25mgml 1
RNase A and incubated overnight at 4 C. FACS data were collected using a
FACSCalibur (BD), and data analysis performed with CellQuest and Flowjo
software. For apoptosis assay, the Apo-ONE Homogeneous Caspase-3/7 Assay
(Promega) was used according to the manufacturer’s instructions. Brieﬂy, 1 105
cells in exponential phase were mixed 1:1 with provided caspase-3/7 substrate.
Caspase activity was measured after 18 h of incubation at room temperature with
constant agitation. The experiment was done in three biological replicates, each
with three technical replicates.
Competition assay. For in vitro competition assay, control and miRNA cells were
seeded in 1:1 ratio (total number of cells 2 105 cells per well, seeded at 1 105
cells per ml). Genomic DNA was extracted at indicated time points by using
DNeasy Blood & Tissue Kit (Qiagen). The relative proportion of the two popu-
lations was estimated by real-time PCR proﬁling of genomic DNA, measuring total
GFP amount and exogenous miRNAs. The speciﬁc measurement of the exogenous
miRNAs was assured by designing set of primers of which one lays within the
vector and the other is within the miR-17-92 cluster (B2m_FW:
50-GGCTCACACTGAATTCACCCCCAC-30 ; B2m_RV: 50-ACATGTCTCGAT
CCCAGTAGACGGT-30 ; miR_FW: 50-CCATCTACTGCATTACGAGCA-30 ;
miR_RV: 50-CGCACACCGGCCTTATTC-30 ; GFP_FW: 50-TGCAGTGCTTCG
CCCGCTACC-30 ; GFP_RV: 50-CCGTCGCCGATGGGGGTGTTC-30).
For in vivo competition, control and miRNA cells were mixed in equal amount
(1:1) and washed twice in PBS. Cells were resuspended in PBS at 3 107 cells per
ml and 100 ml of cell suspension was injected into the tail vein of 16–20-week-old
immunoproﬁcient CB6F1 mice. From the same 1:1 mixture, 1 106 cells were
stored before transplantation as input sample. Lymphocytes were collected from
the spleen of sick animals and subsequently the relative proportion of the two
populations was estimated by real-time PCR. Obtained data were normalized to
B2M and input samples. Results are represented as % of miRNA-expressed cells
versus whole population.
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